HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

The Cyclicality of China Healthcare - Policy Environment, the Industry, and Investment Opportunities

China Healthcare Weekly (Jun.16)- 9th National VBP Update, “Noise” of Consumption Upgrading, ChatGPT

China Healthcare Weekly (Jun.23) - National TCM VBP Results, CDE Changes Game Rule, Hua Medicine

China Traditional Chinese Medicine (TCM) Industry - TCM Is Becoming Indispensable in the Portfolio

BeiGene (6160.HK/BGNE.US) 23Q1 - Qualitative Changes Are Taking Place

Sinopharm Group Co (1099.HK) - Double-Digit Growth Is Expected in 2023; Margins Have Room to Improve

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Thematic (Sector/Industry)

Hong kong Healthcare equipment and services / Thematic (Sector/Industry)

<ul>
<li>According to data, the accumulated balance of medical insurance fund has increased significantly. The core reason of China's medical insurance fee control is to leave room for upcoming difficult period.</li>
<li>The NHSA believes that even under fee control policy, pharmaceutical companies should still be able to achieve good performance. Perhaps companies should review their own problems more than blame policies.</li>
<li>The pricing system in NRDL negotiation has its logical, and the total size of drug market in China reaches several trillion yuan, which is quite large.Why should we be pessimistic?</li>
</ul>


According to data, the accumulated balance of medical insurance fund has increased significantly. The core reason of China's medical insurance fee control is to leave room for upcoming difficult period.
The NHSA believes that even under fee control policy, pharmaceutical companies should still be able to achieve good performance. Perhaps companies should review their own problems more than blame policies.
The pricing system in NRDL negotiation has its logical, and the total size of drug market in China reaches several trillion yuan, which is quite large.Why should we be pessimistic?


The Truth of China Medical Insurance Fund - Time to Clarify Misunderstandings with Investors